Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Should Value Investors Buy SPACs?
by Tracey Ryniec
Value hedge fund managers are launching SPACs in 2020 as value investors struggle to keep up with the return on growth stocks.
Baxter's Clinimix and Clinimix E Injections Receive FDA Nod
by Zacks Equity Research
Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.
Veeva CRM to Help Medis Deliver Customized Experience to HCPs
by Zacks Equity Research
Veeva Systems' (VEEV) CRM will be lending Medis teams a flexible solution that adapts to the unique go-to market strategies of every customer.
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
AngioDynamics Unveils Auryon Atherectomy System for PAD
by Zacks Equity Research
AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.
Accuray's Radixact With Synchrony Used in Japan Hospitals
by Zacks Equity Research
The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
OPKO Health's BioReference Laboratories Introduces NGS Assay
by Zacks Equity Research
OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.
Baxter (BAX) Attains FDA De Novo Authorization for Theranova
by Zacks Equity Research
Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.
Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval
by Zacks Equity Research
Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects
Why Is Merit Medical (MMSI) Up 7.1% Since Last Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Here's Why You Should Retain HMS Holdings in Your Portfolio
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
Thermo Fisher Unveils Suite of Hematology-Oncology Solutions
by Zacks Equity Research
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.
Masimo Releases Favorable Study Results on Pulse Oximetry
by Zacks Equity Research
The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.